Every 8-K that SS Innovations International Inc. (SSII) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SSII and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SSII filings page.
SS Innovations International, Inc. furnished its updated October 2026 company presentation for communications with shareholders and the investment community. It describes the SSi Mantra surgical-robotics platform and reports 244 systems installed and 14,503 multi-specialty surgeries as of September 28, 2026; the installed base spans 12 countries.
Revenue was $42,484,747 in 2025, compared with $20,649,528 in 2024; for the six months ended June 30, 2026, revenue was $25,041,075, compared with $15,120,915 a year earlier. For those six-month periods, gross margin was 49.6%, versus 46.3%, while net loss was $6,243,921, versus $5,938,044. Cash at June 30, 2026 was $22,295,891, including $8,648,461 of restricted cash.
As of September 28, 2026, 195 telesurgeries had been completed with the SSi Mantra; the presentation states India generated approximately 87% of 2025 revenue.
SS Innovations International, Inc. (SSII) reported a corporate update describing continuing progress and milestones for its SSi Mantra surgical robotic platform. The update highlights advances in global expansion, pediatric robotic surgery, robotic telesurgery, and growing installations, procedures, and system utilization.
The company develops the SSi Mantra robotic system and complementary SSi Mudra instruments aimed at making robotic surgery more affordable and accessible worldwide. SSi Mantra is described as a user-friendly, modular, multi-arm system with advanced visualization and tele-surgeon capabilities, and has been clinically validated in India across more than 170 different types of surgical procedures, including cardiac and pediatric surgeries.
SS Innovations International, Inc. (SSII) reported a leadership change in its finance organization. Effective August 21, 2026, Sarah Romano is no longer serving as Chief Financial Officer of the company.
The company stated that Ms. Romano's departure was not due to any disagreement with SS Innovations on matters related to financial reporting, internal controls, operations, policies, or accounting practices.
SS Innovations International, Inc. reported record second-quarter 2026 revenue of $13.9 million, up 39.4% from $10.0 million a year earlier, driven mainly by higher SSi Mantra system sales. First-half 2026 revenue was $25.0 million, an increase of 65.6% from $15.1 million in first-half 2025.
The company’s installed base expanded rapidly, with quarterly SSi Mantra installations rising from 23 to 30 and the cumulative installed base increasing from 105 to 224 systems. Quarterly SSi Mantra surgeries grew from 1,042 to 2,528, and cumulative surgeries from 4,657 to 12,272, indicating increased clinical utilization.
Despite strong top-line growth, SS Innovations recorded a net loss of $2.7 million for Q2 2026 versus a $0.3 million loss a year earlier, as operating expenses, including $2.2 million of stock-based compensation and higher R&D and SG&A, outweighed gross profit. For the first half of 2026, net loss was $6.2 million, similar to the prior year. Cash and cash equivalents increased to $22.7 million as of June 30, 2026, supported by a $18.4 million PIPE financing, while total assets reached $97.0 million and stockholders’ equity rose to $53.4 million.
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system will be showcased at the 2026 Society of Robotic Surgery Annual Meeting in Hollywood, Florida on July 23-26, 2026. The system will be on display, featured in multiple breakout sessions, and used in a livestreamed kidney telesurgery partial nephrectomy between Gurugram and New Delhi, India. Chairman and CEO Dr. Sudhir Srivastava is scheduled to speak and participate in several sessions at the event.
As of July 6, 2026, cumulative multi-specialty procedures completed with the SSi Mantra totaled 12,375, including 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used in over 170 different types of procedures.
SS Innovations International, Inc. appointed Sarah M. Romano as Chief Financial Officer, effective August 3, 2026, under a three-year employment agreement. The agreement provides an annual base salary of $440,000 plus eligibility for an annual performance-based cash bonus.
Romano will receive options under the 2026 Incentive Stock Plan to purchase 750,000 shares of common stock, vesting as to 250,000 shares on the first anniversary and then in 23 monthly installments of 20,833 shares and a final installment of 20,841 shares, subject to continued employment. The contract includes customary confidentiality, proprietary rights, non-competition and non-solicitation covenants and an indemnification agreement. Romano brings more than two decades of financial leadership experience in medical technology and life sciences companies and has helped raise over $100 million through public and private financings.
SS Innovations International, Inc. reported that its subsidiary, the SS International Centre for Robotics Surgery (SSICRS), has graduated its first class from a specialized training course in robotic-assisted cardiac surgery using the Company’s SSi Mantra surgical robotic system at its headquarters in Gurugram, India.
The inaugural program combines classroom instruction with hands-on lab work on the SSi Mantra platform, aiming to train surgeons and other healthcare professionals in advanced robotic techniques. SSICRS plans ongoing condensed five-day courses across multiple specialties, including cardiac, urologic, gynecologic, thoracic, colorectal, gastrointestinal, and general surgery, supported by modern lecture halls, state-of-the-art labs, tele-proctoring, and complementary online modules.
SS Innovations International, Inc. reported that it was named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, an honor given each year to a single surgical robotics company. Management noted that SS Innovations surpassed nine other established finalists, highlighting industry recognition for its SSi Mantra surgical robotic system.
The Company also shared operational milestones. As of June 22, 2026, the SSi Mantra system had been used in 11,719 multi-specialty procedures, including 612 cardiac procedures, 175 telesurgeries and 212 pediatric surgeries, and approximately 2,100 physicians had been trained on the platform across more than 170 procedure types. The SSi Mantra had received regulatory approval in 14 countries, supporting the Company’s goal of making robotic surgery more accessible globally.
SS Innovations International, Inc. entered an ATM Sales Agreement with Virtu Americas LLC to sell up to $50 million of its common stock through an at-the-market offering program. Virtu will act as exclusive sales agent or principal and receive up to 3.0% of gross proceeds from any shares sold.
The sales will be made under the company’s effective Form S-3 shelf registration statement, supported by a new prospectus supplement filed the same day. The agreement includes customary representations, covenants, indemnification and allows either party to terminate in accordance with its terms.
SS Innovations International, Inc. furnished a June 2026 investor presentation highlighting rapid growth in its surgical robotics business. Revenue rose to $42.5M in 2025 from $20.6M in 2024, while gross margin expanded to 46.0% from 40.9%, and net loss narrowed to $8.16M from $19.15M.
The SSi Mantra robotic system has performed 11,270 multi-specialty surgeries with 210 systems installed across 186 hospitals as of May 31, 2026, with no significant safety events reported. For the quarter ended March 31, 2026, revenue was $11.1M, more than double the prior-year quarter, and gross margin reached 48.0%.
The company held $23.6M in cash and no long-term debt as of March 31, 2026, and reported insider ownership of roughly 74% of its 200.1 million shares outstanding as of June 2, 2026. The presentation also outlines ongoing global expansion, with regulatory approvals in India and multiple countries and anticipated EU CE marking in Q4 2026 and a 510(k) pathway toward potential FDA market clearance around Q4 2026–Q1 2027.
SS Innovations International, Inc. reported a major technical milestone: a robot-assisted heart procedure using its SSi Mantra surgical robotic system was successfully performed across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India, described as the world’s longest-distance robotic telesurgery.
The procedure used the optional SSi MantrAsana tele-surgeon console, operated remotely by CEO and cardiac surgeon Dr. Sudhir Srivastava, with the patient-side setup in Indore, India and network latency of 290-300 milliseconds. To date, 22 cardiac telesurgeries and 173 total telesurgeries have been completed using SSi Mantra, which the company states is the only system globally used for robotic cardiac telesurgery.
SSi Mantra has regulatory approval in 14 countries, including India, Guyana, Colombia, Kenya, and the United Arab Emirates, and has been clinically validated in India in more than 170 different types of surgical procedures. The company positions its platform as a modular, multi-arm, 3D 4K-capable robotic system designed to make robotic surgery more affordable and widely accessible.
SS Innovations International, Inc. reported a senior leadership change. On May 18, 2026, Milan Rao informed the company he will step down as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026.
The company stated that it has begun a search process to identify and recruit a permanent successor for the Chief Financial Officer role. No additional details about interim arrangements or reasons for the departure are provided in this report.
SS Innovations International, Inc. reported record unaudited first quarter 2026 revenue of $11.1 million, up about 117% from $5.1 million a year earlier, driven mainly by higher SSi Mantra system and instrument sales. System sales rose to $9.6 million and instruments to $1.2 million, while total revenue increased 116.8%.
Gross profit expanded to $5.3 million from $1.1 million. The company still posted a net loss of $3.6 million, but this improved from a $5.7 million loss in the prior-year quarter as operating loss narrowed. Installations of the SSi Mantra system grew to 26 in the quarter, with a cumulative installed base of 194 systems and 1,859 surgeries performed.
Liquidity strengthened significantly. Cash flows from financing activities included $18.6 million in gross proceeds from a March 2026 private placement, contributing to cash and cash equivalents of $24.0 million at March 31, 2026. Management highlighted ongoing regulatory efforts, including U.S. FDA review of a 510(k) submission and progress toward European Union CE marking for the SSi Mantra.
SS Innovations International, Inc. reported a milestone demonstration of its robotic telesurgery technology. The company announced a successful long-distance cross-border procedure using the SSi Mantra surgical robotic system and the SSi MantrAsana tele-surgeon console, connecting a surgeon in Perth, Australia with a patient in Indore, India over more than 4,500 miles.
On May 2, 2026, Dr. Mohit Bhandari remotely performed a robotic gastrojejunostomy during the Royal Australian College of Surgeons Annual Scientific Congress using the portable SSi MantrAsana console. The company notes that more than 170 telesurgeries, including complex cardiac procedures, have now been completed with SSi Mantra, which has been clinically validated in India in over 100 types of surgical procedures.
SS Innovations International, Inc. reported that more than 10,500 cumulative surgeries have been successfully performed using its SSi Mantra surgical robotic system as of April 30, 2026. These include over 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries across multiple specialties.
The company has installed more than 200 SSi Mantra systems in eleven countries and trained approximately 2,100 physicians, with the platform used in over 170 different procedure types. Management highlights technology features, user-friendliness, and cost advantages as drivers of adoption since commercial launch in August 2022.
SS Innovations International, Inc. filed an 8-K to share a press release about its vision for new surgical robotic technologies unveiled at the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India, which the Company recently hosted.
The Company highlighted four main innovations under development: the SSi Vimana Aero drone-based surgical system, the SSi Avtara humanoid surgical platform, the SSi Operion mobile operating room, and new single-arm robotic endoscopy and ultrasound assist carts. These concepts emphasize remote, mobile and teleoperated care in challenging environments.
At SMRSC 2026, more than 1,600 in-person and 1,800 virtual participants from 19 nations attended. Expert physicians performed 10 live telesurgeries and 13 live robotic surgeries using the Company’s existing SSi Mantra system across multiple specialties. The filing also reiterates standard forward-looking statement cautions.
SS Innovations International, Inc. is hosting the Global Multi-Specialty Robotic Surgery Conference (SMRSC 2026) in New Delhi, India from April 9–11, 2026. This third installment will gather surgeons, innovators and healthcare leaders to discuss the future of robotic and minimally invasive surgery.
Attendance is expected to exceed last year’s event, which drew more than 1,400 in-person attendees and 600 virtual participants from 17 nations. The conference will feature live telesurgeries, robotic surgeries, technology demonstrations and expert panels. The company highlights its SSi Mantra surgical robotic system, which has been clinically validated in India across more than 100 types of procedures.
SS Innovations International, Inc. reported new regulatory approvals for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka and Kenya, expanding its addressable markets in Latin America, the Middle East, Africa and South Asia. The system now has regulatory clearance in eleven countries, including India and the United Arab Emirates. As of December 31, 2025, SSi Mantra’s installed base totaled 168 systems across ten countries, with 7,885 cumulative surgeries performed, including 390 cardiac procedures and 121 pediatric surgeries, plus more than 150 telesurgeries. The company also stated it anticipates U.S. FDA review of its 510(k) submission to be completed by mid‑2026 and believes it can obtain European Union CE marking in 2026.
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The company highlighted that more than 150 cumulative telesurgeries have been successfully performed with SSi Mantra, primarily in India, underscoring growing real‑world use of its platform.
The update describes recent benchmarks, including 18 inter-hospital telesurgeries completed between two Indian cities in eight hours on February 14, 2026, and an earlier 12-hour telesurgery marathon with 24 procedures on December 23, 2025. SS Innovations also announced it will host the Global Multi-Specialty Robotic Surgery Conference 2026 in New Delhi from April 9-11, 2026, where over 20 live telesurgeries using SSi Mantra are planned.
SS Innovations International reported rapid growth for 2025, with revenue rising to $42.5M from $20.6M, driven mainly by higher SSi Mantra system, instrument, and warranty sales. Fourth quarter 2025 revenue reached $14.5M, up sharply from $8.1M, as installations and surgeries increased.
The company reduced its annual net loss to $12.1M from $19.2M, though operating cash flow was negative at $18.5M. Total assets grew to $74.2M and stockholders’ equity to $38.2M, supported by significant financing, including a post‑quarter private placement raising about $18.6M in gross proceeds.
Management highlighted strong adoption of the SSi Mantra in India, expansion into new geographies, and ongoing work toward U.S. FDA 510(k) review targeted for mid‑2026 and European Union CE marking. They anticipate continued strong growth in 2026 as more systems are deployed and robotic procedures scale.
SS Innovations International, Inc. completed a private placement of common stock on March 6, 2026, raising approximately $18.6 million in gross proceeds from the sale of 5,774,839 shares.
The company plans to use the net proceeds for working capital and general corporate purposes, including growth initiatives in India and other existing global markets and preparation for entry into the United States and European Union markets. A $2.5 million non-affiliate investment will trigger a $175,000 cash commission and five-year warrants for 41,667 shares at $3.45 per share to a FINRA member firm. The company expects FDA review of its 510(k) for the SSi Mantra system to be completed by mid-2026 and is pursuing European Union CE marking, which it believes it can obtain in 2026.
SS Innovations International, Inc. filed a current report to share that it has released preliminary, unaudited revenue and other selected operating metrics for the three and twelve months ended December 31, 2025. These figures were disclosed through a press release dated January 13, 2026, attached as Exhibit 99.1.
The company also provided an updated January 2026 Company Presentation as Exhibit 99.2, which it plans to use in communications with shareholders and the broader investment community. All of this information is being furnished under Items 2.02 and 7.01 of the report, meaning it is not treated as filed for liability purposes or automatically incorporated into other securities law filings.
SS Innovations International, Inc. reported a leadership change in its finance function. On January 2, 2026, former Chief Financial Officer Naveen Kumar Amar resigned for personal reasons. The board then appointed Milan Rao as both Global Chief Operating Officer and the new Chief Financial Officer on January 6, 2026, with his roles effective January 16, 2026.
Rao brings more than three decades of executive experience across technology, healthcare and global services, including senior roles at Markets & Markets, Smart Energy Water, Wipro and GE Healthcare. Under a one-year services agreement effective January 16, 2026, he will receive monthly base compensation of $41,667 and a stock grant of 120,000 shares of common stock under the company’s 2016 Incentive Stock Plan, vesting in equal monthly installments of 10,000 shares, subject to continued engagement and plan terms.
SS Innovations International, Inc. reported that it has completed development of five new 5-millimeter surgical instruments intended for clinical use. These instruments are designed for procedures across multiple specialties, including pediatric, cardiac, and head and neck surgery, as well as other operations involving smaller anatomical structures.
The update was disclosed in a current report and accompanied by a press release filed as an exhibit, highlighting expansion of the company’s instrument portfolio for delicate, small-structure surgery.
SS Innovations International, Inc. disclosed that its Chairman and CEO, Dr. Sudhir Srivastava, took part in an interview with Nasdaq’s Live From MarketSite on November 13, 2025, which was published on December 16, 2025. The video can be viewed on Nasdaq’s Live From MarketSite website and via the company’s investor overview page. The company emphasizes that this interview is being furnished, not filed, under Regulation FD and is not incorporated by reference into other SEC reports, and it includes standard cautionary language about forward-looking statements and related risks.
SS Innovations International, Inc. (SSII) furnished an updated November 2025 Company Presentation under Item 7.01 (Regulation FD Disclosure). The presentation is attached as Exhibit 99.1.
The materials are deemed “furnished,” not “filed,” which limits their applicability under Section 18 of the Exchange Act and they are not incorporated by reference into other filings. The notice includes customary forward‑looking statements language, highlighting that actual results may differ due to risks described in the company’s periodic reports.
SS Innovations International (SSII) reported a technology milestone. The company announced the successful completion of the first telesurgery performed using its SSi Mantra Tele Surgeon Console. The system is a compact, self-contained, chair-based version of the larger SSi Mantra command center, designed for portability, smaller spaces, and telesurgery from varied settings, including physician offices.
The announcement was made on November 6, 2025, and a detailed press release was furnished as Exhibit 99.1.
SS Innovations International (SSII) furnished a press release discussing results of operations for the three and nine month periods ended September 30, 2025. The company made the disclosure under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), and attached the press release as Exhibit 99.1.
The information in Items 2.02 and 7.01, and Exhibit 99.1, is deemed “furnished” rather than “filed,” and is not subject to Section 18 liabilities or incorporated by reference into other filings.
SS Innovations International (SSII) announced management participation in two investor conferences. The company will join the UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 11, 2025, and the Stifel 2025 Healthcare Conference in New York, NY on November 12, 2025. The Stifel event includes a group presentation at 4:40 p.m. Eastern Time.
A live webcast and replay of the Stifel presentation will be available on the company’s website at https://ssinnovations.com/investor-overview/. The disclosure is provided under Item 7.01 (Regulation FD) and is deemed “furnished,” not “filed.”
SS Innovations International (SSII) furnished an updated October 2025 Company Presentation under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1 and is intended for communications with shareholders and the investment community.
The information is deemed “furnished” rather than “filed,” meaning it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings. The report also includes standard forward‑looking statements cautionary language.
SS Innovations International, Inc. reported that it has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. The company also stated that it anticipates submitting a 510(k) premarket notification to the U.S. Food and Drug Administration for SSi Mantra for multiple specialty indications in the fourth quarter of 2025. These steps mark progress in the company’s effort to bring its surgical robotic system to the U.S. market, although regulatory clearance has not yet been obtained.
SS Innovations International, Inc. appointed Naveen Kumar Amar as its new Chief Financial Officer, effective September 24, 2025. The change was disclosed in a current report and accompanied by a press release and a formal employment agreement.
Mr. Amar, age 49, brings over 27 years of global corporate finance experience across accounting, audits, capital raising, compliance, taxation, mergers and acquisitions and investor relations. His background includes senior roles at SpiceExpress (the cargo unit of SpiceJet Ltd.), Munchado India, MSD Wellcome Trust Hilleman Laboratories, EDirect Proprietary Ltd. and GE India, and he is both a Chartered Accountant and Company Secretary in India.
The Company and Mr. Amar entered into a five-year employment agreement that provides for a base annual salary of approximately US$163,000, based on current Indian rupee to U.S. dollar exchange rates, and includes customary confidentiality, intellectual property, non-competition and non-solicitation provisions.
SS Innovations International, Inc. reported that the world’s first pediatric pyeloplasty telesurgery was successfully performed using its SSi Mantra surgical robotic system. This means a complex kidney-related procedure in a child was carried out remotely with the help of the company’s robot-assisted platform, highlighting a significant technical and clinical milestone for its technology. The company furnished a press release with additional details as an exhibit to this report.
SS Innovations International, Inc. reported a technology milestone, disclosing that it successfully completed the first robotic telesurgery performed from its bus mobile robotic telesurgery unit. This procedure was announced in a company press release and highlights the use of its robotic system in a mobile, remote-surgery setting. The press release describing the event is filed as an exhibit to the report.
SS Innovations International, Inc. (Nasdaq: SSII) filed a Form 8-K dated 15 July 2025 to disclose an operational milestone. The company reports that it has now installed more than 100 SSi Mantra surgical robotic systems across India and six other countries. Collectively, the installed base has facilitated over 5,000 surgical procedures, including 240 cardiac surgeries and 32 telesurgeries.
The filing contains no revenue, earnings, guidance or transactional information; it simply furnishes the related press release as Exhibit 99.1. While financial details are absent, the figures provided highlight growing clinical adoption and an expanding geographic presence for the Mantra platform.